CBR1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2760094	0.78	6/20
SCHEMBL982797	0.59	4/20
SCHEMBL980159	0.50	4/20
SCHEMBL979572	0.47	4/20
SCHEMBL981025	0.46	4/20
SCHEMBL4570242	0.60	3/20
SCHEMBL980671	0.51	3/20
SCHEMBL979386	0.51	3/20
SCHEMBL978163	0.50	3/20
SCHEMBL980799	0.50	3/20
SCHEMBL978895	0.49	3/20
SCHEMBL980408	0.49	3/20
SCHEMBL978668	0.48	3/20
SCHEMBL980380	0.48	3/20
SCHEMBL979968	0.47	3/20
SCHEMBL980848	0.47	3/20
SCHEMBL978586	0.47	3/20
SCHEMBL979803	0.47	3/20
SCHEMBL980797	0.47	3/20
SCHEMBL593493	0.71	2/20

Clinical trials — most relevant to CBR1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Atorvastatin, Aspirin, Oxidative Stress, Coagulation and Platelet Activation Indexes	PHASE4	UNKNOWN
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons	PHASE4	COMPLETED
Role of Antioxidants Supplementation in Chronic Pancreatitis	PHASE3	COMPLETED
Pharmacogenetics of Nicotine Addiction Treatment	PHASE3	COMPLETED
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease	PHASE2	COMPLETED
Base Editing for Mutation Repair in Hematopoietic Stem & Progenitor Cells for X-Linked Chronic Granulomatous Disease	PHASE1/PHASE2	RECRUITING
Dose-Ranging Study for Miconazole Oil for Treatment of Otomycosis	PHASE2	COMPLETED
A Study for Assessing the Efficacy and Safety of BH4 in Radiation Enteritis	PHASE2	UNKNOWN
GSNOR Phenotyping/GSNO Challenge in Severe Asthma	EARLY_PHASE1	COMPLETED
Involvement of Pollutants in Atopic Dermatitis and Psoriasis	nan	UNKNOWN
SWOG 8897-A DNA Analysis in Predicting Treatment Outcome in Women With Breast Cancer in SWOG 8897	nan	COMPLETED
Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome	nan	COMPLETED
Immunological Profile and Clinical Characteristics of Children Diagnosed With Chronic Granulomatous Disease	nan	UNKNOWN
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	nan	UNKNOWN
NCF Gene & TNFSF4 in SLE Patients	nan	UNKNOWN
Cell Signaling and Resistance to Oxidative Stress: Effects of Aging and Exercise	nan	COMPLETED
A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis	nan	UNKNOWN
Mucomyst for Hepatitis C	nan	SUSPENDED
Role of Nox2 in CNI-induced Renal Fibrosis	nan	COMPLETED
Lung Mucus Hypersecretion and NQO1	nan	COMPLETED
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione	nan	COMPLETED
Reactive Oxygen Species Following Aortic Valve Replacement	nan	COMPLETED
Covid-19: Possible Role of Neutrophil Extracellular Traps	nan	UNKNOWN
Gene-by-Smoking Interactions and Risk of Atherosclerosis - Ancillary to ARIC	nan	COMPLETED
Forced Oscillometry in Infants With Bronchopulmonary Dysplasia	nan	RECRUITING
Pharmacogenomics of Antidepressant Response in Children and Adolescents	nan	COMPLETED
The Safety and Efficacy Study of RiaGev in Healthy Adults	nan	UNKNOWN
Environmental and Biological Monitoring Pilot Study for Polycyclic Aromatic Hydrocarbons in Linxian, China	nan	COMPLETED
Tecfidera Diffusion Tensor Imaging	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a CBR1 binder may also engage these)

Protein	Name	Similarity
Q5RCU5	—	0.998	Q5RCU5 →
Q8MI29	—	0.991	Q8MI29 →
Q3SZD7	—	0.971	Q3SZD7 →
P48758	—	0.971	P48758 →
P47727	—	0.960	P47727 →
P47844	—	0.945	P47844 →
B2GV72	—	0.937	B2GV72 →
Q8K354	—	0.932	Q8K354 →
Q67FW5	—	0.929	Q67FW5 →
B2GV54	—	0.927	B2GV54 →
Q86V21	—	0.921	Q86V21 →
Q3ZBV9	—	0.920	Q3ZBV9 →
Q5NVN7	—	0.918	Q5NVN7 →
Q2HJ19	—	0.918	Q2HJ19 →
Q71R50	—	0.917	Q71R50 →
Q9N0E1	—	0.917	Q9N0E1 →
Q8BLF1	—	0.917	Q8BLF1 →
Q5R8Y5	—	0.917	Q5R8Y5 →
Q5E9T4	—	0.917	Q5E9T4 →
Q6UWP2	—	0.917	Q6UWP2 →
Q0IID9	—	0.916	Q0IID9 →
Q3U0B3	—	0.915	Q3U0B3 →
SAE1	SUMO-activating enzyme subunit 1	0.915	landscape →
Q9R0M5	—	0.914	Q9R0M5 →
Q6GL10	—	0.914	Q6GL10 →
Q9CQ65	—	0.914	Q9CQ65 →
GSTP1	Glutathione S-transferase P	0.914	landscape →
Q9H3S4	—	0.914	Q9H3S4 →
Q28960	—	0.914	Q28960 →
GK	Glycerol kinase	0.913	landscape →